C4 Therapeutics (CCCC) investor relations material

Vision and strategy

• Aims to become a fully integrated biopharmaceutical company focused on targeted protein degradation (TPD) for oncology and INN (inflammation, neuroinflammation, neurodegeneration) diseases.

• Building a sustainable pipeline with best-in-class and first-in-class degraders, validated pathways, and large market opportunities.

• Leveraging platform collaborations to expand TPD reach and generate non-dilutive capital.

• Cash runway expected through end of 2028, supporting execution beyond key value inflection points.

Clinical pipeline and milestones

• Cemsidomide, an IKZF1/3 degrader, is in Phase 2 (MOMENTUM trial) for late-line multiple myeloma and Phase 1b in combination with elranatamab.

• Additional trials planned for cemsidomide in combination with other therapies, with key data readouts and regulatory milestones expected through 2028.

• Discovery pipeline advancing novel degraders for INN diseases, with three potential INDs targeted by 2028.

Cemsidomide in multiple myeloma

• Positioned as a potential best-in-class IKZF1/3 degrader, relevant across multiple lines and combinations in a large, growing market.

• Phase 1 data show compelling anti-myeloma activity, wide therapeutic index, and differentiated safety profile.

• Ongoing and planned trials aim to establish cemsidomide as a foundational therapy and partner of choice for MM treatment.